In this media release from the currently ongoing ESMO 2018 Congress in Munich, Germany new data from the continuing STAMPEDE trial in the UK and Switzerland is confirming that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.
However, the data also shows that in men with a higher disease burden there are not any overall survival advantages to be obtained from ablative radiation.
Joel T Nowak, MA, MSW
